10-QPeriod: Q3 FY2024

Bunge Global SA Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 30, 2024For Securities:BG

Summary

Bunge Global SA reported a significant decrease in net income for the nine months ended September 30, 2024, with net income attributable to Bunge shareholders at $535 million, a substantial drop from $1,627 million in the same period last year. This decline is primarily attributed to lower gross profit in the Agribusiness segment and reduced performance across both Core and Non-core segments. Diluted earnings per share also saw a considerable decrease to $3.73 from $10.71 year-over-year. The company is actively navigating the complex regulatory and financing landscape surrounding its pending acquisition of Viterra, having secured significant debt financing and issued new senior notes. Bunge also completed the divestiture of its 50% stake in BP Bunge Bioenergia. Despite the overall decrease in profitability, the company maintained a strong liquidity position, with cash and cash equivalents increasing to $2,836 million. Investors should monitor the progress and impact of the Viterra acquisition and the company's efforts to manage commodity price volatility.

Financial Statements
Beta

Key Highlights

  • 1Net income attributable to Bunge shareholders decreased significantly to $535 million for the nine months ended September 30, 2024, down from $1,627 million in the prior year.
  • 2Diluted earnings per share fell to $3.73 for the nine months ended September 30, 2024, compared to $10.71 for the same period in 2023.
  • 3Total Segment EBIT decreased by 62% to $1,025 million for the nine months ended September 30, 2024, primarily driven by lower gross profit in the Agribusiness segment.
  • 4The company completed the sale of its 50% ownership in BP Bunge Bioenergia on October 1, 2024, for an approximate net amount of $828 million.
  • 5Bunge secured $8.0 billion in acquisition financing for the Viterra acquisition and issued $2.0 billion in Senior Notes on September 17, 2024.
  • 6Cash and cash equivalents increased to $2,836 million as of September 30, 2024, indicating a solid liquidity position.
  • 7The company repurchased $600 million of its shares during the nine months ended September 30, 2024, as part of an ongoing share repurchase program.

Frequently Asked Questions

The primary reasons for the significant decrease in net income and earnings per share are lower gross profit in the Agribusiness segment and reduced performance across both Core and Non-core segments. This was exacerbated by factors like lower average sales prices in processing and merchandising, and unfavorable mark-to-market results in certain areas.

Bunge has secured $8.0 billion in acquisition financing, with $2.0 billion raised through the issuance of Senior Notes on September 17, 2024. The remaining $6.0 billion commitment is in place. The acquisition is subject to regulatory approvals and other customary closing conditions, with the expectation to close in the coming months. Bunge is also undertaking exchange offers and consent solicitations related to Viterra's existing debt.

Bunge completed the sale of its 50% ownership in BP Bunge Bioenergia on October 1, 2024, for approximately $828 million. This divestiture will impact the company's Sugar and Bioenergy segment results in future reporting periods, which has shown significantly lower EBIT in the current period. A refundable deposit of $103 million related to this sale was recognized in Other current liabilities as of September 30, 2024.

Total debt increased to $6,195 million as of September 30, 2024, primarily due to the issuance of $2.0 billion in Senior Notes for the Viterra acquisition financing. Despite the increase in debt, Bunge maintained a strong liquidity position, with cash and cash equivalents increasing to $2,836 million. The company has substantial committed borrowing capacity available under its revolving credit facilities.